NMS·Healthcare·$1.0B·#114 / 520 in Healthcare
AMPH Amphastar Pharmaceuticals, Inc.
62SOLID
CATEGORY BREAKDOWN
GROWTH0
QUALITY60
STABILITY75
VALUATION98
GOVERNANCE99
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-1.7%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
49.5%
69
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
83.2%
25
< 25% strong
Price / Sales
Market cap relative to trailing revenue
1.4x
98
< 3x strong
Rule of 40
Growth rate plus operating margin
18
47
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
29.3%
99
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-27.3%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE AMPH WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when AMPH's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.